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Abstract 
In-vitro Model System for Calcific Band Keratopathy 
and Inhibitory Effects of C60 Fullerene Derivatives 
by 
Nadjmeh Doostdar 
Calcific band keratopathy (CBK) is a degenerative condition resulting in the 
deposition of calcium salts in the superficial layers of the cornea and causing significant 
visual disturbance and pain of the affected eye. The amount of CBK precipitates 
recovered from the affected eye is very small rendering a great challenge in development 
of an effective and non-invasive treatment for this condition. This provides an impetus to 
study the possible chemical factors that may contribute to the development of CBK in an 
effort to develop a more efficient and un-intrusive treatment for this condition. To this 
end, we have developed an in-vitro model system resembling band keratopathy's 
chemical composition and morphology thus providing insight to the mechanism of 
formation and allowing for mass production of the material furthering the advances of 
therapeutic targeting CBK. Our study is the fIrst to demonstrate that low molecular 
silicon can assist in the formation of CBK. Given the predominance of calcium and 
presence of silicon in CBK material, we have investigated the effect of calcium and 
silicon chelators on our reference and synthetic samples. Our results reveals nitrilo-
tris(methylene) phosphonic acid, citric acid, and fructose as promising choices for 
chelation therapy for band keratopathy. 
The unique structural, physical, and photo-, electro-chemical properties of 
buckminsterfullerne C60 and its derivatives have rendered them particularly interesting 
for the field of nanomedicine. Toward this end, we have synthesized and investigated a 
series of derivatized C60 fullerenes possessing amine and amino acid pendant groups as 
inhibitors of the zinc enzymes carbonic anhydrases (CAs) and the human 
immunodeficiency virus type I aspartic protease (HIV -1 PR). Computational studies were 
performed in order to shed light in understanding the inhibition mechanism of CAs by 
these derivatives. Our collaborative investigation reveals that the CA isoforms show 
diverse inhibition profiles with our fullerene derivatives. Both computational and 
experimental techniques confirmed anti HIV -1 PR inhibitory effects of our C60 
derivatives. Additionally, we have synthesized a series of C60 fullerene-peptides in order 
to investigate their cellular uptake, interference in vitro with specific DNA binding and 
inhibition of neuroblastoma cell growth. Our in vitro cell studies show that these 
fullerene-peptides are capable of penetrating into cytoplasm of the JF neuroblastoma cells. 
Cell viability study was undertaken in order to examine the biological response of our 
fullerene peptides for neuroblastoma cell proliferation. 
"To laugh often and much; to win the respect of intelligent people and the affection of 
children; to earn the appreciation of honest critics and endure the betrayal of false friends; 
to appreciate beauty; to find the best in others; to leave the world a bit better, whether by 
a healthy child, a garden patch or a redeemed social condition; to know even one life has 
breathed easier because you have lived. This is to have succeeded." 
Ralph Waldo Emerson 
Acknowledgements 
I would like to express my sincerest of gratitude to my professor Dr. Andrew 
Barron for the excellent guidance, thoughtful inputs and cordial milieu that he provided 
me throughout my program at Rice University. I would also like to place on record my 
thankfulness and appreciation to my committee members Prof. Lon Wilson, Prof. Mason 
Tomson, and Dr. Marshall Hamill for their invaluable contributions and painstaking 
effort in going through this manuscript. Special thanks go to Dr. Jianhua Yang of Baylor 
College of Medicine, Dr. Serdar Durdagi, Dr. Thomas Mavromoustakos, Dr. Manthos 
Papadopoulos with the National Hellenic Research Foundation and Dr. Cllaudiu Supran 
of University of Florence for their productive collaboration. 
Thanks to all the members of the Barron group for helping me on countless 
number of occasions, academically and personally, and I wish you and your families all 
the very best. To Dr. Jianzhong Yang and Carissa Manrique who helped me immensely 
in getting started and progress with this study, I thank you. 
To the wonderful faculty, partiCUlarly Dr. Mary McHale and staff, especially Jane 
McNeal, thank you for making my experience at Rice a wonderful one. I would also like 
to thank the staff of Shared Eqiupment Authority, Angelo, Bo, Rich and Wenh for their 
support. Special thanks to Dr. Rolf Arvidson for his dedication and support with the VSI 
analyses. 
I must acknowledge my undergraduate academic advisor, Prof. Ramiro Sanchez, 
for believing in me and encouraging me to further my education in the field of chemistry. 
Special thanks to all my friends for their support and friendships. 
Finally, thank you to my parents for making my education as the top priority of 
their life and to my sisters for their love and moral support. I could not have made it 
without you. Mehdi, thank you for our two beautiful daughters and for being with me 
through thick and thin. Sara and Sahar, thanks for all the love and support I could ever 
ask for and more. I hope you both know that I recognize the sacrifices you have made to 
help me get through graduate school. 
Dedicated to my dear parents and beautiful daughters 
Table of Contents 
Introduction 1 
Chapter 1. Synthesis of an In-vitro Model System and Therapeutics Studies for 
Calcific Band Keratopathy Precipitate 
Introduction 
Results and Discussion 
Conclusions 
Experimental 
References 
Chapter 2. Biological Effects of Functionalized Buckminsterfullerene (C60) 
Introduction 
Results and Discussion 
Conclusions 
Experimental 
References 
14 
19 
47 
52 
54 
56 
60 
78 
79 
81 
IX 
List of Figures 
Introduction 
Figure 1.1. External appearance of CBK in the eye. Image is courtesy of 
Dr. Hamill of Cullen Eye Institute at Baylor College of Medicine. 1 
Figure 1.2. Schematic represents the role of functionalized fullerenes as 
important nanomaterials in biomedical applications. 4 
Figure 1.3. Molecular structure ofC6o (a) and the related bond length (b). 5 
Figure 1.4. Molecular modeling image of the HIV -1 protease. Color coding 
is as follows. Yellow: Leu, Ile, Phe, Tyr, Val, Trp, Pro, Gly, Ala. 
Blue: Lys, Arg. Red: Asp, Glu. Cyan: Thr, Ser, GIn, Asn, Cys, Met, 
His. The C60 is colored magenta. 7 
Figure 1.5. Structure of Gd@C6o. 8 
Chapter 1 
Figure 1.1. Schematic representation ofthe reaction between phosphonic acid 
and calcium carbonate: (a)surface etching and dissolution of calcium 
carbonate by phosphonic acid, (b )formation of soluble calcium 
phosphonate complex. 16 
Figure 1.2. Arrangement oftwo oxolanediolato ligands at a hydroxosilicon 
center. 18 
Figure 1.3. High-resolution XP spectra for eye sample P2 (a) Ca2p3/2 and (b) 
Si2p. 21 
Figure 1.4. Raman spectrum of human eye sample PI showing peaks associated 
with various silicates. 
Figure 1.5. SEM image of eye samples PI (a) and P2 (b) revealing small fused 
spherical shapes ~ 1 - 3 Ilm in size. The samples were taken from 
22 
x 
human patients at Baylor College of Medicine. 23 
Figure. 1.6. SEM images of calcium silicate grown in the presence of (a) SDS 
(sample 1) and (b) fumed silica (sample 2) showing the presence of 
typical crystallites of CaC03. 26 
Figure 1.7. SEM image of sample 3 showing the presence of fused spherical 
features in a matrix. 27 
Figure 1.8. Plot of sphere size as a function of Si:Ca ratio for eye samples PI 
and P2 in comparison with synthetic samples 3 and 20. 28 
Figure 1.9. SEM images of samples prepared with (a) 4x the silica (sample 4) 
and (b) 1/2X the silica (sample 6) as compared to sample 3. 31 
Figure 1.10. SEM image of sample 7 formed using silicic acid. 32 
Figure 1.11. SEM images of sample 10 formed using silicone oil as the silicon 
source. 33 
Figure 1.12. SEM images of sample 13 . 35 
Figure 1.13. SEM images of(1) sample 14 and (b) sample 15 showing the effect 
of adding a non-polar compounds (hexane) to the calcium/silica 
reaction. 
Figure 1.14. SEM images of (a) sample 16, and (b) sample 17 showing the 
formation of very small non-fused spheres with the addition of 
hexane and dodecane, respectively. 
Figure 1.15. SEM image of sample 19. 
Figure 1.16. SEM images of sample 20 showing the formation of highly 
37 
37 
38 
fused spheres. 39 
Figure 1.17. Raman spectra of sample 20. 40 
Figure 1.18. High-resolution XP spectra of sample 20 (a) Ca2P312 and 
(b) Si2p. 41 
Figure 1.19. VSI maps of sample 20 surface (80X objective) showing the 
initial surface ( a), and reaction sequence of this surface exposed 
Xl 
to H6ntmp solution at 15 min (b), 30 min (c), and 1 h (d). 44 
Figure 1.20. VSI maps of sample 20 surface (1 Ox objective) of the initial 
surface (a) and reaction of this surface exposed to citric acid 
solution at 1 min while removing solvent (b), at 1 min. after solvent 
removal (c). 45 
Figure 1.21. VSI maps of sample 20 surface (80X objective) of the initial surface 
(a), and reaction sequence of this surface exposed to fructose 
solution at 1 h (b), and 3 h (c). 
Figure 1.22. 31p NMR spectra ofH6ntmp solution (a) and its reactions with 
2 mg (b), 6 mg (c), 10 mg (d), and 14 mg (e) ofCaC03• 
Figure 1.23. 31 p NMR spectra ofH6ntmp solution (a) and its reactions with 
46 
48 
2 mg (b), 4 mg (c), 8 mg (d), and 16 mg (e) of sample 20. 49 
Figure 1.24. IR of citric acid and citric acid complex. 50 
Chapter 2 
Figure 2.1. Active site of a-CA enzymes (Zn2+ is shown as a pink sphere 
and histidines in green). 59 
Figure 2.2. Compounds synthesized for HIV -1 P and CAs inhibition studies. 60 
Figure 2.3. The binding interactions of compound 2.1 with (S) configuration 
at *Cl with the active site residues ofHIV-l P. 63 
Figure 2.4. The binding interactions of compound 2.1 with (R) configuration 
at *Cl with the active site residues ofHIV-l P. 
Figure 2.5. The binding interactions of compound I with the active site 
residues of HIV -1 P. 
64 
65 
xu 
Figure 2.6. Binding offullerene 2.1 to hCA II (shown as ribbon representation 
of the amide backbone). The catalytic Zn(II) ion is the yellow sphere 
at the center of the molecule. 68 
Figure 2.7. Binding of fullerene 2.5 to hCA II as obtained by the induced 
fit docking method. Yellow and green dashed bonds show 
H-bonds and close-van der Waals contacts, respectively. The 
catalytic Zn(II) ion is shown as orange spheres. 70 
Figure 2.S. Binding of compound 2.3 to hCA IX. Yellow and green dashed 
bonds show H-bonds and close-van der Waals contacts, respectively. 
The catalytic Zn(II) ion is shown as the yellow sphere. 71 
Figure 2.9. Superimposition ofhCA II (shown in yellow colored ribbons) and 
hCA IX (shown in green colored ribbons) docking complexes of 
fullerene 2.3. Dark colored fullerene shows the binding pose at 
hCA II and light colored fullerene shows the binding pose at hCA IX. 
The Zn(II) ion is shown by yellow (for hCA II) and green (for hCA 
IX) sphere, respectively. 72 
Figure 2.10. The basic helix-Ioop-helixlleucine zipper ofMyc family proteins. 73 
Figure 2.11. Fluorescence images of JF cell incubated with (a) F-K(FITC)-
NDLRSAFATLRDHV and (b) Baa-K(FITC)-
NDLRSAFATLRDHV. 75 
Figure 2.12. Inhibition offullerene peptides against the proliferation of 
neuroblastoma cell line (SH-SY5Y), (2.10, e), (2.11, e), 
and (2.12, .). 76 
Figure 2.13. Inhibition of fullerene peptides against the proliferation of 
neuroblastoma cell line (SH-SY5Y), (2.9, e), (2.10, e), 
and (2.11, .). 76 
X1l1 
Figure 2.14. IMR-32 neuroblastoma cellline proliferation in DMSO, and 
Baa-peptides 2.10 and 2.12. 77 
Figure 2.15. LAN-l neuroblastoma cell line proliferation in DMSO, 
and Baa-peptides 2.10 and 2.12. 77 
Figure 2.16. LAN-l neuroblastoma cell line proliferation in DMSO, and 
Baa-peptides 2.10 and 2.12. 78 
List of Tables 
Chapter 1 
Table 1.1. Summary ofXPS data for eye samples and selected 
synthetic samples. 20 
Table 1.2. The Si:Ca ratios as determined by XPS and sphere sizes as 
determined by SEM of selected samples. 24 
Table 1.3. Summary of reaction conditions for the formation of CBK model 
materials in the absence of hydrocarbon. 25 
Table 1.4. Selected binding energies obtained from high resolution XPS data. 30 
Table 1.5. Summary of reaction conditions for the formation of CBK model 
materials in the presence of hydrocarbon. 36 
Chapter 2 
Table 2.1. Comparison of experimental and computational binding energies 
the fullerene derivatives at HIV -1 P. 62 
Table 2.2. Inhibition of mammalian carbonic anhydrase isozymes with 
fullerene derivatives. 66 
Table 2.3. Computational binding energies of fullerene derivatives to 
CA II and CA IX. 69 
Table 2.4. Peptide sequences and cell lines studied. 74 
Baa 
Boc 
C60 
DC 
ca. 
CBK 
D 
() 
DNA 
EQ 
eV 
FITC 
H 
HPLC 
Hz 
1.e. 
IR 
kJ 
mg 
IlL 
/lm 
/lM 
mL 
MS 
mm 
Abbreviations 
Bucky amino acid, fullerene phenylalanine 
tert-buty loxidencarbony 1, -C( O)OC( CH3)3 
Buckminsterfullerne, [60] fullerene 
degree centigrade 
circa, approximately 
calcific band keratopathy 
degree 
delta, chemical shift (NMR) 
deoxyribonucleic acid 
equation 
electron volt 
fluorescein isothiocyanate 
hour 
high-performance liquid chromatography 
hertz 
id est, that is (to say) 
infrared spectroscopy 
kilo joule 
milligram( s), 10-3 g 
microliter( s), 10-6 L 
micrometer(s), 10-6 m 
micromolar, 10-6 M 
milliliter(s), 10-3 L 
mass spectrometry 
minute(s) 
MALDI-MS 
nm 
NMR 
ppm 
SEM 
VSI 
XPS 
matrix-assisted laser desorption ionization mass spectroscopy 
nanometer, 10-9 m 
nuclear magnetic resonance spectroscopy 
part per million 
scanning electron microscopy 
vertical scanning interferometry 
X-ray photoelectron spectroscopy 
1 
Introduction 
Band Keratopathy. Calcific band keratopathy (CBK), first named by Dixon in 
1848 as a "calcareous film of the cornea", refers to the usually slow and gradual 
accumulation of calcific minerals in a band shape limited to the exposed interpalpebral 
zone of the cornea (Figure 1.1).1,2 This condition generally appears as a variably dense 
opacification of the peripheral cornea that spreads with time into the central cornea. The 
deposited material is a non-crystalline form of calcium deposited in the superficial layers 
of the cornea.3 It is known that the initial stages of precipitation occur in Bowman' s layer, 
the basement membrane of the corneal epithelium.4 Holes in the calcific band are present 
where the corneal nerves penetrate the Bowman' s membrane resulting in a picture that 
resembles "Swiss cheese". 5,6 
Figure 1.1. External appearance of CBK in the eye. Image is courtesy of Dr. Hamill of 
Cullen Eye Institute at Baylor College of Medicine. 
2 
While the initial stages of CBK are asymptomatic, as it progresses epithelial 
defects and surface irregularities can develop. The usual presenting symptoms of CBK 
are ocular pain and photophobia due to corneal epithelial erosions and decreased vision 
or even blindness resulting from opacification of the cornea.? 
CBK can occur in the setting of a variety of chronic ocular or systematic diseases 
such as end stage glaucoma and chronic intraocular inflammation (e.g., juvenile 
rheumatoid arthritis). 8,9,10 Multiple case reports suggest an association between 
development of CBK and use of oils in endothelial touch during retinal surgery.ll,12,13 
Despite all the existing experimental and clinical reports for CBK, little is thus far known 
about the pathogenesis and etiology of this condition. Development of a model system in-
vitro can be very useful in understanding the pathology and chemistry of CBK and most 
importantly, in exploration of therapeutic targeting of CBK. 
Treatment alternatives for this condition are limited. Palliative options include 
simple lubrication and the use of bandage contact lenses for comfort. In some mild cases 
this approach may be satisfactory. For more advanced cases these treatments become 
ineffective and surgical intervention to debulk the calcific deposits and a restoration of 
the corneal surface is required. Surgical approaches to remove the calcific deposits 
include surgical keratectomy with a blade or burr, excimer laser photokeratectomy, and 
chemical chelation. These treatment options are less than satisfactory as they are 
frequently associated with significant post treatment pain, discomfort, and a delay in 
visual recovery .14 In addition, keratectomy by any method results in loss of corneal tissue 
and surface irregularity. The metal complexing agent ethylenediaminetetraacetic acid 
(EDT A, I) has been found to provide some benefit by softening the CBK precipitate 
allowing for easier removal. However, this treatment is far from ideal given that EDT A is 
not specific to calcium and can potentially bind to any metal, therefore, causing adverse 
side effects. Unfortunately none of these treatments address the causative factors or 
3 
prevent further calcium deposition. In order to better treat this condition, a more efficient 
method of breaking-up or dissolving the CBK precipitate without disrupting the corneal 
tissue or disturbing the surface anatomy is desirable. More importantly, perhaps, is the 
need to develop a treatment approach to prevent the deposition in the first place thus 
treatment alternatives that can prevent CBK from forming also need to be studied. In 
order to accomplish this goal it is necessary to better understand the chemical conditions 
that promote the formation of the CBK precipitate. Chapter 1 of this thesis describes a 
systematic investigation towards formation of precipitates mimicking the calcium 
materials of CBK. It also details the use of various chemical extractors and their 
medicinal effect on our synthetic material. 
o 
o 
(I) 
C6o-based nanomaterials for enzyme inhibition and DNA binding. 
Nanomedicine, an important branch of nanotechnology, has emerged as a new field of 
research for diagnostics and therapeutics. The field of nanomedicine refers to highly 
specific design and development of nanomaterials at the molecular scale for identifying 
and curing diseases. Multifunctional liposomal nanoparticles, functionalized fullerenes, 
4 
functionalized nanotubes, iron oxide nanoparticles, polymeric micelles, dendrimers, 
nanoshells, and polymeric microspheres are amongst the investigated nanomaterials in 
the field of medicine (Figure I.2).15 
Functionalized C60 fullerenes have become an important member of the rapidly 
growing nanomedicine family. This is due to the unique physical, chemical, optical and 
electronic properties of the C60 nanosphere core. These derivatives have shown enzyme 
inhibition, anticancer, antibacterial, cell signaling, DNA and genomic activities, 
photodynamic activation, and antioxidant properties. 
pes of nanopartlcles 
Nanomedicine 
Figure 1.2. Schematic represents the role of functionalized fullerenes as important 
nanomaterials in biomedical applications. 15 
Buckyball or buckminsterfullerene (C60) consists of 60 carbon atoms arranged in 
the form of a truncated icosahedron with 12 pentagonal faces which are fully surrounded 
by 20 hexagonal faces (Figure I.3). 16 Each carbon atom is bonded to three others and is 
Sp2 hybridized. Buckminsterfulleme (C60) has two bond lengths: the [6-6] ring bonds 
between two hexagons which due to their considerably higher double-bond 
5 
characteristics are shorter than the [6-5] ring bonds between a hexagon and a pentagon. 17 
The diameter of this molecule is 0.7 nm. 17 
Although pristine C60 is sufficiently soluble in carbon disulfide and in aromatic or 
chlorinated hydrocarbons, it is sparingly soluble or aggregates easily in many other 
organic solvents and it is virtually insoluble in polar solvents and aqueous media. This 
great obstacle hampers the practical applications of this molecule, especially its 
biological applications. 18 , 19 Therefore, the covalent functionalization of C60 has been 
explored vigorously in order to overcome this hurdle and to a great extent has solved the 
problem?O,21,22,23 These explorations have allowed the preparation of highly soluble C60 
derivatives while preserving the unique physical, chemical, optical and electronic 
properties of the C60 core. Therefore, the research for potential applications of these 
water-soluble fullerene derivatives in medicinal chemistry has been significantly 
increased in recent years. 
1.45 A [5,6] 1.38 A [6,6] 
(b) 
Figure 1.3. Molecular structure ofC6o (a) and the related bond length (b). 
With a diameter of about 1 nm, which is the same as the opening of the active site 
entrance or the interface of subunits of many enzymes, C60 spheroid has become an 
6 
appealing candidate for enzyme inhibition studies.24, 25 One of the first applications of 
biologically active C60 was proposed by Friedman et al. in 1993 (Figure 1.4).26 By means 
of molecular modeling, they proposed that C60 and its derivatives can be inhibitors of 
HIV -1 protease (HIV -1 P) due to their complementary fit with the hydrophobic cavity of 
the enzyme. Their subsequent in-vitro studies with a series of water soluble fullerene 
derivatives confirmed the inhibition effects of these derivatives in the low micromolar 
concentration range?? Other researchers have studied anti HIV -1 P activity of a variety of 
fullerene derivatives since then showing similar inhibition results.24 
The unique hollow space inside of the C60 fullerene cage has attracted wide 
interest for incorporation of metal ions resulting in a novel form of fullerene-based 
material labeled endohedral metallofullernes.24 This new class of fullerenes are 
particularly interesting because of their promising applications in the field of nuclear 
medicine. 28 , 29 The major disadvantage of the current radiopharmaceutical drugs 
containing chelated radioisotopes of metals used in radiomedicine and diagnostic 
radiology is their in-vivo kinetic instability which can allow the release of small 
quantities of toxic radiomaterials.30 In an endohedral metallofullerene, the metal is placed 
in the fullerene cage and has no chance of escaping out providing a distinct advantage 
over the current metal chelate complexes (Figure 1.5). Wilson and colleagues have been 
the pioneers in the pursuit of utilizing holmium and gadolinium containing 
meatllofullerenes as new therapeutic and magnetic resonance imaging (MRI) contrast 
agents.31 ,32 Their studies have revealed that metallofullerenes can act as radiotracers and 
as contrast enhancing agents for magnetic resonance imaging (MRI) with fundamental 
advantages over commercially-available chelate compounds with respect to improved 
physiological stability and lack of acute toxicity. 
Besides the striking size and geometric features, C60 also demonstrate a variety of 
interesting photophysical properties. The extended 1[- conjugation of the fullerene cage 
7 
allows it to transition from a short-lived singlet excited state to a long-lived triplet excited 
state upon irradiation with visible or UV light generating reactive oxygen species 
(ROS).33,34 These reactive 
oxygen species (ROS) react with a wide range of biological targets and are known to be 
involved in both cellular signaling and cell damaging. On the other hand, it has been also 
reported that C60 can function as a "free radical sponge" and quench various free 
radicals more efficiently than conventional antioxidants due to the delocalized 7t double 
bond system of the fullerene cage.35,36 This unique dual nature of C60 fullerene and its 
derivatives to either quench or generate ROS has rendered them as promising candidates 
for a variety of biological applications including: DNA photo-cleavage,37 photodynamic 
therapy (PDT),38 neuroprotection,39,4o antimicrobial and antiapoptotic activities.41 ,42 
Figure 1.4. Molecular modeling image of the HIV -1 protease. Color coding is as follows. 
Yellow: Leu, lIe, Phe, Tyr, Val, Trp, Pro, Gly, Ala. Blue: Lys, Arg. Red: Asp, Glu. Cyan: 
Thr, Ser, GIn, Asn, Cys, Met, His. The C60 is colored magenta?6 
8 
Figure 1.5. Structure of Gd@C60 .43 
Hydrophobicity is another important property of C60 which has been utilized in 
design of novel compounds for potential applications in drug, peptide, protein and gene 
delivery into living cells for therapeutic purposes.44,45,46,47,48,49 Paclitaxel is regarded as 
one of the most promising drugs against lung cancer with a cytotoxicity more dependent 
on its exposure time than its increased concentration.44 A fullerene-paclitaxel conjugate 
designed by Wilson and colleagues to slowly release the drug for aerosol liposome 
delivery of paclitaxel. This slow-release drug-delivery system showed significant 
anticancer activity in tissue culture. Our group has previously reported a novel approach 
to formation of cell penetrating peptides using fullerene-peptide conjugates. We have 
demonstrated that the hydrophobic fullerene core plays an important role in the delivery 
of theses fullerene-peptides to either the cytoplasm or nucleus of the cel1.45 
Functionalized C60 fullerenes have also been explored as transfection vectors to deliver 
exogenous DNA into cells and their ability to mediate gene transfer has been tested.47 It 
is known that the DNA-binding ability of a molecule depends both on its hydrophobicity 
and cationic charge and the binding becomes stronger as the molecule becomes more 
hydrophobic and more cationic. 50 Aminofullerenes have shown to effect transfection with 
an efficiency as high as the common lipid-based transfection agents. 
9 
In addition to the foregoing described potential medicinal applications of 
functionalized C60 fullerene, there are many other promising investigations for 
biomedical applications of C60 fullerene compounds. Functionalized amino acid and 
peptide based fullerenes have been found to activate enzymes involved in the oxidative 
deamination of biogenic amines.46 Fullerene-substituted amino acid incorporated into 
peptides have shown significant effects on the secondary structures and self assembly of 
properties of these peptides.51 Successful selected tissue targeting has been reported using 
a fullerene-based materia1.52 Fullerene and its derivatives are also promising candidate for 
design of various composite biomaterials.53 
Research on functionalized C60 fullerenes has dramatically changed their impact 
in medicinal chemistry. With creative and collaborative participation of scientists from 
various disciplines, C60 fullerene and its derivatives will see many more new biomedical 
applications that will serve to increase the quality of life. Chapter 2 of this thesis 
describes our recent achievements in this field with regards to inhibition activities of a 
series of functionalized C60 derivatives from our previously synthesized library of 
fullerene derivatives against HIV -1 protease and carbonic anhydrase isoforms. It also 
describes the synthesis of a series of novel fullerene-base amino acid peptides for 
investigation of their cellular uptake and nueroblastoma cell growth inhibition. 
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Chapter 1 
Synthesis of an In-vitro Model System and Therapeutics Studies for 
Calcific Band Keratopathy Precipitate 
Introduction 
14 
It is well known that calcific band keratopathy is the result of precipitation of 
calcium salts on the corneal surface (directly under the epithelium), and that serum and 
normal body fluids (e.g., tears) contain calcium in concentrations that approach their 
solubility product; however, this does not explain what factors promote precipitation in 
some subjects and not in others. Is there an external trigger that promotes the formation 
of the CBK precipitate? Since CBK is a rare disease and none of the in-vivo studies thus 
far have been able to identify the cause and pathogenesis of CBK, development of an ex-
situ model system, heretofore unavailable, would be of obvious importance for shedding 
light into the mysteries behind formation of this disease. 
In addition, biological samples of band keratopathy deposits are very small 
making experimentation to test new therapies difficult if not impossible. Given the 
limited quantities recoverable from treatment of band keratopathy (1 - 5 mg) it would be 
desirable to have a model material on which potential complexing/digestion agents can be 
tested. To be successful this material must be easily produced for further testing, and also 
allow an understanding of the factors involved in the formation of CBK material in the 
human eye. 
In this regard we have characterized samples from individual patients by scanning 
electron microscopy (SEM), X-ray photoelectron spectroscopy (XPS), and X-ray 
diffraction (XRD) and Raman spectroscopy with a view to replicate its structure, 
morphology, and composition in an easily prepared model analog. In designing the model 
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material we have considered some of the environmental conditions and exposures that 
promote CBK. 
Conventional treatments are limited and do not address the basic pathophysiology 
of the condition. Given the predominance of calcium in CBK material it would be 
reasonable to expect that one form of treatment would involve the specific complexation 
and dissolution of calcium. Complexation of calcium from solid materials has been 
extensively studied with regard to the processes that control cement setting and 
retarding. 1 In this regard, the Barron research group has previously reported that cement 
retarders used in the oil industry, such as phosphonic acids in particular, nitrilo-
tris(methylene)phosphonic acid, N[CH2PO(OH)213 (H6ntmp, I), are highly effective at the 
extraction of calcium from cementitious minerals.2,3 
(I) 
The initial steps of the proposed mechanism of action for the phosphonic acid 
with the calcium mineral surface are shown schematically in Figure 1.1. It is possible that 
a similar mechanism could occur for calcium chelation in the eye with H6ntmp or a 
similar calcium chelator. The complexation will allow the calcium to become soluble, 
therefore able to wash out in solution. The calcium complex could either be excreted 
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through the nasolacrimal duct into the nose which leads either to the maxillary sinus or 
the throat or the solution can expelled out of the eye directly. Therefore, H6ntmp was 
chosen for our calcium complexation studies for the synthetic samples. 
(a) phosphonic acid 
(b) 
[> I <\ \l <\ ~ 
\l [> \l ~ calcium carbonate 
11111111111111111111111 
11111111111111111111111 
11111111111111111111111 
calcium phosphonate complex 
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•••••••••••• 
Figure 1.1. Schematic representation of the reaction between phosphonic acid and 
calcium carbonate: (a)surface etching and dissolution of calcium carbonate by 
phosphonic acid, (b ) formation of soluble calcium phosphonate complex.3 
As an alternative to the phosphate ligands, study of other extracting agents, such 
as citric acid (II), to help prevent the growth of CBK is of great interest. Citric acid is a 
promising choice for chelation therapy for band keratopathy, since it is naturally 
produced in the body to complex with excess calcium in the kidneys to avoid the 
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formation of kidney stones.4,5 It could thus be an ideal molecule to utilize for CBK 
treatment. One drawback in using citric acid is that it can be harmful to the eye; therefore, 
a very low concentration will be used to assure the patient's safety. Citric acid has been 
studied to reduce corneal ulcers in alkali eye burns. A 10% citrate solution was used to 
treat eyes and no major negative side effects occurred in the eyes of the patients.6 
Therefore, we believe that citric acid at a 10% or lower concentration will remain safe to 
the patients. 
(II) 
The possibility of treatment is further complicated by our findings that human 
sourced samples of band keratopathy material contain significant concentrations of 
silicon in the form of a calcium silicate.7 The hydration of calcium silicate minerals to 
form hydrated silicates is what gives cement its strength. Therefore, we believe excess 
silicon could also be a cause for CBK and chelation therapy could decrease the 
probability of its formation. This further suggests that silicon chelators may be viable 
treatments. A possible solution for silicon chelation is incorporating the use of 
monosaccharides. They are inexpensive and readily available; so they qualify as a good 
practical candidate. Also, monosaccharides are naturally occurring in the vitreous humor 
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of the eye, so they should not be harmful to patients and they are representative of the 
conditions within the eye.8 When silicon is che1ated to sugar, it forms a five coordinate 
syn species, Figure 1.2.9 The 1,2 diol group with the anomeric hydroxyl is needed to form 
the cis-isomer for the chelating reaction to occur. The cis-conformation is able to occur if 
the stability constant is more than the isomerization energy. 
OH 
I 
0:751,0 __ 
• __ 0'" O--c. 
Figure 1.2. Arrangement of two oxolanediolato ligands at a hydroxosilicon center. 9 
In this regard we have investigated the medical effects of chemical extractors 
specific to calcium and silicon on our synthetic samples. The two molecules chosen in 
this study to complex with calcium are nitrilo-tris-(methylene)phosphonic acid (H6ntmp) 
and citric acid. Fructose (open-chain and ring structures, III) is the most common sugar 
with the highest cis formation, and therefore it was chosen as our starting lead candidate 
for silicon chelation (Scheme 1.1). Vertical scanning interferometry (VSI) was used to 
monitor surface reactivity, topographical changes and the evolution of surface 
composition in real time with the aim of validating the ability of our complexing agents 
to form ligands or dissolve calcium and silicon. The ability of H6ntmp to bind to calcium 
was further confirmed and quantified using 31 P NMR analysis. IR analysis was conducted 
in order to adduce that calcium is indeed binding to citric acid. 
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(III) 
Result and Discussion 
In the effort to determine the most accurate model for CBK growth, experiments 
were developed to test the factors that aid the formation of CBK type material. Multiple 
samples were synthesized mimicking the formation of the CBK material based on 
experimental analysis of the biological CBK material. Trends were noted based upon 
three factors: the presence of silicon, calcium and a lipid layer. Initial instrumental 
analyses on the human CBK samples were conducted for comparison to the synthetic 
material. 
CH~H 
0 
HO H HOH2C 
srt-t 
H OH lit 
H OH 
HO 
H~H 
Scheme 1.1. Silicon-monosaccharide complex structure.9 
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Analysis of human eye samples. In order to determine a synthesis approach for 
the proposed synthetic material the elemental composition of human CBK samples 
obtained from two patients (pt and P2) was determined by XPS. The XPS data for the 
eye samples from different patients show the presence of calcium, carbon, oxygen, and 
silicon.7 The quantitative elemental concentration results for the eye samples obtained 
from high resolution XPS analysis are reported in Table 1.1. The Si:Ca ratio ranges from 
2.0 to 4.3 between samples, but is constant across each individual sample, suggesting that 
the composition is dependent on the patient. The elemental analysis of the samples 
obtained from human patients is interesting in two regards. First, the lack of detectable 
quantities of phosphorous in the XPS « 0.1%) suggests that the role of phosphorous may 
be less important in CBK growth as previously have been suggested. IO,11 Second, the 
presence of silicon and the correlation of morphology with the silicon:calcium ratio 
suggest that silicon compounds may be important in the fonnation of CBK deposits. It 
must be noted that the presence of nitrogen in one of the patient's samples may suggest 
that the identity of biologically sourced organic matter has an effect on the composition 
and fonn of the precipitate. 
Table 1.1. Summary ofXPS data for eye samples and selected synthetic samples. 
Sample C(%) 0(%) Si (%) Ca(%) N(%) 
Pt 65.1 21.7 3.4 1.7 7.0 
P2 76.0 19.1 3.9 0.9 0.0 
3 65.8 25.5 0.9 2.7 0.0 
6 64.8 27.6 3.3 4.2 0.0 
to 72.8 24.0 0.1 3.1 0.0 
20 60.9 30.8 5.5 2.7 0.0 
(a) 
Counts 
(arb units) 
(b) 
Counts 
(arb units) 
360 356 352 348 344 340 
Binding energy (eV) 
114 11 0 1 06 1 02 98 94 
Binding energy (eV) 
Figure 1.3. High-resolution (a) Ca2p3/2 and (b) Si2p XP spectra for eye sample P2. 
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Peak fitting of the high-resolution Ca (2P3/2) and Si (2p) XP spectra indicated the 
presence of calcium carbonate and silicates, respectively (Figure 1.3). Based upon the Ca 
(2P3/2) spectra, it would appear that the calcium peak in the human sample P2 can be 
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interpreted as being between that observed for the two polymorphs: calcite and vaterite.12 
Although the values for the synthetic materials are intermediate, they appear to be closer 
to those of vaterite. While vaterite is a metastable phase it does occur naturally in mineral 
springs, organic tissue, gallstones, and urinary calculi. The human samples were handled 
in non-silicone materials and were washed with DI water and MeOH prior to analysis to 
ensure that the silicon was not a surface contaminant due to handling. Furthermore, argon 
ion $puttering of the surface does not alter the Ca:Si ratio significantly. This indicates that 
the silicon is not a surface contaminant, but part of the bulk composition. This is 
confirmed in part by the Raman spectra of the eye samples (Figure 1.4) that indicate the 
presence of silicates (375, 392, 820, and 845 em-I) in general and a band at 1750 em-I , 
which is indicative ofCaSi03 . 
1400 
1200 
1000 
375 & 392 cm-1 
silicate 
/ 821 & 843 cm-1 
Intensity 800 1750 cm-1 
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400C~~/~~ 200 
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o 500 1000 1500 2000 2500 3000 3500 
Wavenumber (cm-1) 
Figure 1.4. Raman spectrum of human eye sample PI showing peaks associated with 
various silicates. 
SEM images of the eye samples show that the topography of the human eye 
sample contains small agglomerates resembling fused spherical shapes (Figure 1.5) 
within a matrix whose size ranges from 1 - 3 !-lm in diameter. The size of the spheres is 
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related to the Si:Ca content of the samples. In eye sample PI where this ratio is 2:1, the 
spheres are smaller than the spheres in eye sample P2 where the ratio is more than 
doubled (Table 1.2). 
Figure 1.5. SEM image of eye samples PI (a) and P2 (b) revealing small fused spherical 
shapes,..., 1 - 3 Jlm in size. The samples were taken from human patients at Baylor College 
of Medicine. 
Based upon Raman spectroscopy as well as the presence of silicon in the XPS 
(even after sputtering) we suggest that silicon is an important component (and possible 
co-causative) of CBK.7 Silicon as a nidus for calcium deposition is seen within the body 
during bone calcification. Silicon levels decrease drastically approaching maturity 
suggesting silicon is important in bone growth and mineralization of calcium within the 
bones. 13 Silicates are also important in the hydration of calcium silicate minerals to form 
hydrated silicates in cement. 14 Since silicon is known to act as a nidus for calcium growth, 
its presence in the human samples is consistent with its function as a nucleation site. The 
fusing of the spheres indicates that overgrowths of spheres were occurring. The large 
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percentage of carbon in the sample is due to lipids found on the outer layers of the eyes 
from tears and pores around the eyelid. I5 Based upon the appearance of fused spheres that 
are similar to the silica spheres obtained in the presence of surfactants,I6 we can suggest 
that the spheres in the human samples are a result of the surfactant (Le., lipid material) 
acting as a template of silica/silicate growth. We have proposed, therefore, that excess 
silicon could also be a causative factor in CBK and silicon chelation therapy could play a 
role in treatment and prevention of the condition.7 One issue to note is that the Si:Ca ratio 
appears to have significant latitude while maintaining the general morphology observed. 
Table 1.2. The Si:Ca ratios as determined by XPS and sphere sizes as determined by 
SEM of selected samples. 
Sample Si:Ca from XPS Sphere size (Ilm) 
HI 2 1-2 
H2 4.3 1-3 
3 0.3 0.1 
20 2.03 3 
Independent effects of surfactant and silicon. In order to mimic the 
composition of the eye sample, various molar ratios of reagents were assessed. Table 1.3 
summarizes the reaction conditions of each sample. With regard to the calcium source, 
we note that while our studies used pre-formed calcium carbonate, in the eye this 
probably results from the reaction of calcium salts with carbon dioxide, either from the 
atmosphere or dissolved. 
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Table 1.3. Summary of reaction conditions for the formation of CBK model materials in 
the absence of hydrocarbon. a 
Sample CaC03 Fumed silica Silicic acid Silicone oil SDS TDPA Time 
(mg) (mg) (mg) (mL) (mg) (mg) (h) 
1 200 20 4 
2 200 20 4 
3 200 20 20 4 
4 200 80 60 4 
5 200 160 60 4 
6 200 10 60 4 
7 100 60 20 4 
8 100 30 20 4 
9 100 15 20 4 
10 200 0.5 60 4 
11 150 20 300 4 
12 150 20 150 4 
13 100 2 20 4 
21 200 20 20 24 
a SDS = sodium dodecyl sulfate; TDPA = tetradecylphosphonic acid. 
In the first set of experiments the effect of a surfactant (SDS, IV) alone on the 
calcium carbonate solution was tested (synthetic sample 1). Although SDS is not present 
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in the body, it was chosen to simulate the lipids that would be present in the pre-ocular 
tear film and ocular tissues,15 and because we have previously observed its ability to seed 
spherical particles of silica. 16 The SEM image of this sample showed the formation of 
calcium carbonate sheet like structures as shown in Figure 1.6a. The sheet-like 
morphology is typical for calcium carbonate precipitation in the absence of a template. 17 
Elemental analysis performed by XPS, Raman and XRD all confirmed the presence of 
CaC0
3 
crystals. It is clear, therefore, that a surfactant-like chemical is insufficient to form 
calcium spheres and that the presence of silicon is important in creating the CBK -type of 
material. 
Figure. 1.6. SEM images of calcium silicate grown in the presence of (a) SDS (sample 1) 
and (b) fumed silica (sample 2) showing the presence of typical crystallites ofCaC03. 
The effect of silicon (fumed silica) on the CaC03 precipitation in the absence of a 
surfactant was also studied (Table 1.3, sample 2). This sample developed jagged sheets 
(Figure 1.6b) that resembled the appearance of sample 1. The Raman and XRD analysis 
of this sample mainly showed calcium carbonate in the final product. Again, the 
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formation of a CBK-like deposit is not simply a function of the presence of calcium and 
silicon. 
(IV) 
Combined effects of surfactant and silicon. The influence of silicon in the 
formation of CBK when added to a calcium carbonate solution in the presence of SDS 
was examined in sample 3 (Table 1.3). In the presence of silicon, the morphology of the 
structures changed from sheets to spheres (Figure 1.7), having a closer resemblance to the 
biological sample (c./, Figure 1.5). The spherical shapes are smaller in size (l00 nm) 
than observed in samples PI and P2; however, the size appears to be broadly dependant 
on the Si:Ca ratio (Figure 1.8), suggesting that the spheres are silicon rich. 
Figure 1.7. SEM image of sample 3 showing fused spherical features in a matrix. 
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XPS data showed that this sample was composed of carbon, oxygen, silicon, and 
calcium (Table 1.1). The elemental percentages of carbon and oxygen in this sample 
closely resembled the ones observed in the human eye samples, however, this sample is 
much more calcium rich in compare to the eye samples having a Si:Ca of 0.3:1. As 
observed with the two eye samples, the increased calcium content results in smaller 
sphere sizes. Therefore, the small sphere sizes observed in sample 3 are believed to be 
due to its high calcium content. Curve fitting of the Ca and Si regions of sample 3 
obtained from high resolution XPS indicated the presence of calcium carbonate and 
silicates, respectively (Table 1.4), which match the data from the human samples; 
however, the Raman spectra of sample showed the presence of both calcium carbonate 
and silica, but not specific silicate phases. This latter observation suggests that biological 
mineralization is more prevalent than chemical crystallization. 
3 
2 
Sphere size 
(nm) 
O+-~--~~--~~--r-~--r-~~ 
o 2 3 4 5 
Ca:Si ratio 
Figure 1.8. Plot of sphere size as a function of Si:Ca ratio for eye samples PI and P2 in 
comparison with synthetic samples 3 and 20. 
29 
While the . synthetic samples can mimic the composition and morphology of the 
human eye samples, the crystallinity and crystal phases were not the same. In an effort to 
see if this is a function of crystal growth, sample 3 was thermally annealed at 500°C (for 
2 and 4 hours) and then at 700 °C (again for 2 and 4 hours). The Raman spectrum and 
XRD were collected after each stage. Raman spectra of annealed samples at both 
temperatures revealed a dramatic decrease in their signals of crystalline CaC03 and 
showed no signals indicative of silica in compare to sample 3. The low signal intensity 
for CaC03 may be due to decomposition of the sample into CaO at these temperatures 
although no CaO was detected. These results are supported by the XRD data. Data 
derived from the X-ray patterns of the annealed samples demonstrated the presence of a 
predominant calcium carbonate phase ( calcite), similar to XRD patterns of sample 3; 
however, intensity of these lines was much weaker. Additionally, no diffraction lines 
related to silica or silicate appeared in the XRD patterns of the annealed samples. In 
biological systems, crystal growth is greatly influenced by local factors present in the 
system such as surfactant like lipids and other organic molecules, neutral pH, temperature, 
and presence of ions. IS Although care was taken to mimic the biological environment 
closely, due to the complexity of the biological systems it was merely impossible to 
emulate the same settings for our artificially crystal growth systems. Additionally, in 
contrast to synthetic samples that are prepared in a short period of time, mineralization 
processes including CBK calcification usually progress very slowly. Given the inevitable 
differences among the synthetic and biological samples reaction conditions and times, 
above observed disparity in Raman data is not unreasonable. 
Our findings strongly suggest a correlation between the presence of silicon and 
the formation of CBK. In addition, the lack of surfactant in sample 2 which resulted in 
production of non-spherical shapes confirms the need for a lipid (or lipid-like additive). 
In agreement with our previous studies,14 it seems SDS aids sphere formation by possibly 
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making micelles, which act as a template for silicon deposition and ultimately Ca-Si 
fused complex formation. 19 As a result, it appears the interaction of the silicon and 
calcium with biological lipids is a major factor in the development of CBK. This system 
was proposed as our initial CBK model material. 
Table 1.4. Selected binding energies obtained from high resolution XPS data. 
Sample Binding Energy (e V) 
Si2p Ca 2P3/2 
H2 102.02 346.91 
3 102.52 347.37 
20 103.08 347.27 
Si02 103.1-103.8 
Silicates 102.0-102.9 
CaC03 346.5 - 347.9 
Effect of silicon concentration and source. The effects of various silicon and 
surfactant sources and reaction time on the precipitate's morphology were investigated. 
The concentration of fumed silica was varied (in comparison to our initial CBK model 
material) in order to determine effect of the silicon concentration on the sphere size. 
When the amount of fumed silica was increased by four and eight fold (samples 4 and 5, 
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respectively, see Table 1.3) the SEM images showed formation of very small semi-
spherical shape (100 nm) crystals (Figure 1.9a). 
Figure 1.9. SEM images of samples prepared with (a) 4x the silica (sample 4) and (b) 
1/2X the silica (sample 6) as compared to sample 3 (see Figure 1.6). 
Raman and XRD data confirmed the presence of calcium carbonate and silicon in 
the products. The increase in the amount of silica does not seem to affect the morphology 
of the structure but the size and chemical composition of the material does not match 
with ones found in either of the human eye samples (PI and P2). Lowering the amount of 
fumed silica (as compared to sample 3) produced crystals (sample 6) with similar 
chemical composition to the eye samples; however, the SEM image (Figure 1.9b) showed 
development of large cubic aggregates >5 ~m in size. 
While the choice of fumed silica as a silicon source was chosen based upon our 
prior research,16,20,21 it is important to determine if any form of silicon could initiate the 
formation of CBK -like material. To test this theory, silicic acid was selected as an 
alternative silicon source. Silicic acid is the form of silicon predominantly absorbed by 
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humans and is found in numerous tissues including bones, tendons, aorta, liver, and 
kidney.22 Reactions performed with various concentration of silicic acid as the silicon 
source all failed to create a product which resembled the eye sample (samples 7 - 9). 
SEM images of these samples (e.g., Figure 1.10) showed sheet like structures. 
Figure 1.10 .. SEM image of sample 7 formed using silicic acid. 
Silicone oil has been associated with the formation of CBK in the eyes of many 
patients when administered to cure retinal tears, and other surgeries, including: 
proliferative vitreoretinopathy proliferative diabetic retinopathy, and other retinal 
detachments (RDS).23 Silicone oil is injected into the eye, to replace the vitreous gel, at 
the time of surgery for the repair of retinal detachments. Several long-term studies have 
shown that calcific band keratopathy can occur in up to 16% of aphakic eyes after 
silicone oil injection and in up to 100% of eyes with silicone oiVendothelial touch.23,24 
Further evidence for the effects of silicon on ocular calcification came from the 
experience of hydrogel intraocular lenses (lOL) which were packaged in a silicon-gasket 
packaging system known as the Surefold® system. Patients developed calcium deposits 
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on these IOLs within 29 months of implantation?5,26,27 Therefore, silicone oil was chosen 
as an alternative source of silicon for this study. Sample obtained from this reaction 
(sample 10) showed formation of fused semi-spherical shapes of ca. 5 J.lm (Figure 1.11) 
relatively more similar to the shape and morphology of the fused spheres observed in the 
eye samples in comparison to our preceding synthetic samples. When compared to the 
results of the human eye samples, the XPS data of sample 10 showed similar quantity of 
carbon and oxygen, however, the calcium content is much higher and the amount of 
silicon is significantly lower as listed in Table 1.1. The Raman and XRD both revealed 
the presence of CaC03 and silicon in the final product. 
Figure 1.11. SEM images of sample 10 formed using silicone oil as the silicon source. 
Effect of surfactant concentration and source. With the aim of mimicking 
CBK material more precisely, the outcomes of varying amounts and type of surfactant on 
the selected CBK model material were examined next. Notwithstanding we did not 
observe significant quantities of phosphorous in either of the eye samples, it has been 
reported that phosphonate salts are sometimes found in CBK samples. lO, l1 Therefore, a 
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phosphonic-capped surfactant was chosen, tetradecyl phosphonic acid (TDP A, V), as the 
alternative surfactant source, which is a biological lipid signaling molecule. 
(V) 
Increased amount of SDS in the reaction (Table 1.3, sample 11) caused formation 
of fused cubic structure with characteristic peaks of calcium carbonate observed in both 
Raman and XRD spectra. When SDS was replaced with TDPA (sample 12), in presence 
of fumed silica as the silicon source, a sheet like structure was formed. This sample 
showed characteristic peaks of CaC03 in Raman and formation of Ca-Si bond in XRD. 
When silicone oil and TDP A were used as the sources of silicon and surfactant, 
respectively (sample 13), the final product showed formation of fused semi-spherical 
shapes (Figure 1.12) comparable to the shape and morphology of the spheres observed in 
the eye samples but much larger in size ca. 10 - 25 J.lm. This morphology was also seen 
in our previous sample (sample 10) that was prepared with silicone oil. These results not 
only indicate that silicone oil might be a good silicon source for formation of synthetic 
CBK, it also further confirms the role of silicon in formation of biological CBK. 
Effect of hydrocarbon. The presence of non-polar compounds that are present in 
the human eye, were also tested to determine their influence on formation of CBK 
materials. Hexane was chosen as a model aliphatic compound to examine the effect of a 
non-polar hydrocarbon with our model system. Although, hexane is not present in the eye, 
35 
it is a simple non-polar hydrocarbon, which is readily available and would certainly 
provide insight into changes associated with the presence of non-polar species. On the 
other hand, the non-polar compounds that compromise the eye typically have higher 
carbon ratios; therefore, dodecane was also used in our system separately to study the 
possible effect of using a longer carbon chain (Table 1.5). 
Figure 1.12. SEM images of sample 13 . 
The growth of CaC03 crystals in the presence of hexane and surfactant (SDS) 
showed development of large sheets and small particulate shapes «100 nm) (sample 14). 
These shapes (Figure 1.13a) do not resemble those seen in the eye sample (Figure 1.5). It 
is our belief that hydrocarbons act as a template for CaC03 crystal growth here. On the 
other hand, when the growth was performed in presence of hexane and silicone (fumed 
silica) alone, a cubic morphology was observed as seen in Figure 1.13b (sample 15). This 
reaction failed to make spherical shapes as seen in the eye sample that is consistent with 
the theory that the surfactant lipid layer acts as a template for calcium-silica formation. 
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Table 1.5. Summary of reaction conditions for the formation of CBK model materials in 
the presence of hydrocarbon. a 
Sample CaC03 Fumed Silicic Silicone SDS TDPA Hexane Dodecane Time 
silica acid oil 
(mg) (mg) (mg) (mL) (mL) (mg) (mL) (mL) (h) 
14 200 0 20 20 4 
15 200 20 20 4 
16 200 20 20 20 4 
17 200 20 20 20 4 
18 200 200 20 20 4 
19 200 20 10 20 4 
20 100 1 15 20 4 
22 200 20 20 20 24 
aSDS = sodium dodecyl sulfate; TDPA = tetradecylphosphonic acid. 
The reaction of calcium carbonate, fumed silica and SDS in presence of hexane 
formed spherical shapes about 50 nm in diameter (sample 16); however, these spheres 
were not fused in a matrix as observed in the biological samples. All instrumental 
analysis including XRD, XPS and Raman confirmed the presence of both silicon and 
calcium carbonate. Similarly, this reaction in presence of dodecane as the hydrocarbon 
source produced spherical shapes about 10 nm in diameter (sample 17). It seems the 
addition of hydrocarbon to our initial CBK model material induces the formation of 
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smaller spheres and using the longer hydrocarbon chain has little to no effect on the 
system. Figure 1.14 demonstrates the SEM images of these two samples. 
Figure 1.13. SEM images of (1) sample 14 and (b) sample 15 showing the effect of 
adding a non-polar compounds (hexane) to the calcium/silica reaction 
Figure 1.14. SEM images of (a) sample 16, and (b) sample 17 showing the formation of 
very small non-fused spheres with the addition of hexane and dodecane, respectively. 
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When the silicon source was changed to silicic acid, the SEM image of the final 
product showed sheets of material about ca. 5 J.lm in size (sample 18). This result is 
similar to our earlier results where silicic acid was used as the silicon source in absence 
of hydrocarbon. However, silicic acid in presence of TDP A as the surfactant source 
(sample 19) formed semi-spherical CaC03 crystal ca. 5 - 10 J.lm in size (Figure 1.15). 
Figure 1.15. SEM image of sample 19. 
Finally, the reaction of silicone oil and TDPA, as the respective sources of silicon 
and surfactant, with calcium carbonate in the presence of hexane was investigated. The 
SEM image of this sample (sample 20) showed fused spherical shapes that are very 
similar to the shape and morphology of the human eye samples as shown in Figure 1.16. 
According to the XPS data, the Ca: Si ratio of this sample is the nearest to the Ca: Si of the 
human eye samples, more specifically to eye sample PI (Table 1.2). Although, the 
Raman spectrum of this sample is rather complex due to the addition of the siloxane to 
the system (Figure 1.1 7), the XRD and high resolution XPS both show the presence of 
calcium carbonate and silicon in the final product. 
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Figure 1.16. SEM images of sample 20 showing the fonnation of highly fused spheres. 
The high-resolution Ca (2P3/2) and Si (2p) peaks for sample 20 (Figure 1.18) are at 
347.27 eV and 103.08 eV, respectively, which can be compared to those of pure CaC03 
(346.6 eV) and Si02 (103.3 eV). The similarity suggests the presence of similar chemical 
identity (Table 1.4). In comparison to all our other synthetic samples, sample 20 has one 
of the closest resemblances to the human eye samples with regard to morphology, sphere 
size, and chemical composition. 
Effect of reaction time. Samples 3 developed the spherical morphology as seen 
in the original eye samples (PI and P2) but the size of the spheres was smaller than the 
ones seen in the eye samples. Although the size of the fused spheres is clearly dependant 
on the Si:Ca ratio, it is also possibly a function of the slower in-vivo reaction rates. Thus, 
in an effort to control the size of the spheres, we experimented with the reaction time. 
The chemicals used in sample 3 were reacted over 24 hours to test if the spheres found in 
the SEM image of sample 3 would increase in size. According to SEM extended reaction 
times (sample 21) failed to create spherical shapes. This reaction was then repeated in 
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presence of hexane for 24 hours (sample 22) that also failed to create spherical shapes. 
Based on these two samples, we believe over time the calcium/silica spheres are forming 
large aggregates creating large sphere/cube like structures. 
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Figure 1.17. Raman spectra of sample 20. 
In the effort to determine the respond of our developed synthetic model system to 
the chosen chemical extractors we conducted a series of dissolution studies. We used 
calcium carbonate and fume silica as starting reference materials and sample 20 which 
had the closest resemblance to the human eye samples as our synthetic model material for 
these studies. We also monitored the reaction of sample 20 with all of our complexing 
agents in real time utilizing VSI. Additionally, we monitored and verified the 
complexation of H6ntmp with calcium carbonate and sample 20 using 31 P NMR. Reaction 
of citric acid with sample 20 was also confirmed with IR. 
Sample dissolution. With the aim of dissolving the CBK material more 
efficiently, the outcomes of varying concentration and pH of solutions on the reference 
material were examined first. Both calcium carbonate and fume silica showed no 
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Figure 1.18. High-resolution XP spectra of sample 20 (a) Ca2p3/2 and (b) Si2p. 
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significant dissolution in 1 % solutions of H6ntmp, citric acid and fructose in DI water 
with adjusted pH of 7. Although CaC03 initially dissolved completely in 5% solutions of 
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H6ntmp and citric acid with adjusted pH of 7, the dissolution was slow and after 24 hour, 
precipitates were formed. When pH of H6ntmp solution was adjusted to 6.5, dissolution 
occurred slowly but no precipitate formation was observed after 24 hours. Calcium 
carbonate reacted spontaneously and completely with 5% citric acid solution of pH 6.5. 
Fume silica, on the other hand, showed no dissolution in a 1 % or 5% fructose solution of 
pH 7, but when pH was adjusted to 6.5, complete dissolution occurred and no precipitate 
formed after 24 hrs. These results indicated that at the 5% solution concentration with pH 
of 6.5 not only dissolve the reference material but prevent precipitation of the ligands or 
complexes as well. This concentration and pH were chosen for further VSI, NMR and IR 
studies of sample 20. 
Sample 20 completely dissolved in 5% H6ntmp and citric acid solutions and no 
precipitate formed even after 24 hours. Dissolution of sample 20 in the 5% fructose 
solution was none or insignificant. This result is not surprising considering that this 
sample contains only about 5% silicon material. 
VSI experiments. Sample 20 was reacted with 50 ~m of H6ntmp solution for 15 
min, 30 min, and 1 h. Figure 1.19 show the evolution of surface topography with reaction 
time. We can observe a distinguished reaction sequence: an initial surface etching 
followed by subsequent precipitation. This result is consistent with reaction steps 
reported by our group's previous study.3 First, a rapid surface etching occurs which brings 
about an overall reduction in surface height of about 15 ~m along with increase in surface 
area and roughness. Next is a slow growth phase in which the surface shows an increase in 
height of 5 ~m. This stage is associated with the formation of a calcium phosphonate 
complex. Formation of the calcium phosphonate precipitates in eye should not be of any 
concern since the complex will be excreted out the eye via tears through the nasolacrimal 
duct soon after formation and before precipitation. 
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Due to earlier bench-top observation of the quick reaction of CaC03 with citric 
acid solution, we decided to monitor reaction of sample 20 with this solution at 1 min 
intervals. After application of 50 Ilm solvent, a large etch pit was formed within the first 
minute of reaction. The surface height change observed for this reaction was about 25 Ilm 
and no significant change was observed after the initial pit formation (Figure 1.20). This 
observation not only confirms our former results that sample 20 completely dissolves in 
citric acid solution it also verifies that sample remains dissolved till removed from the 
surface. No surface change was observed following the first minute of reaction due to 
complete dissolution of the sample material in the solvent and its removal upon solvent 
aspiration. 
Reaction of sample 20 with fructose solution was monitored for' 15 min, 30min, 1 
h and 3h and no surface topography change was observed (Figure 1.21). The overall 
surface height remained the same throughout the reaction. This result is comparable with 
our bench-top studies of sample 20. Even though we had seen complete dissolution of 
fume silica in this solution no dissolution was observed for sample 20 during our bench-
top studies. Silicon composition in sample 20 is infinitesimal in compare to fume silica, 
therefore, the result obtained from the VSI analysis seems reasonable and no further 
chelation studies of this solution was carried out. 
Spectroscopic studies. Complexation of H6ntmp with calcium carbonate was 
monitored by 31p NMR spectroscopy. Calcium carbonate was incrementally added to a 
solution of H6ntmpID20 with adjusted pH of 6.5 over time and ligand formation was 
monitored against the 5% H6ntmpID20 standard solution. The 31p NMR spectra of the 
standard solution showed a triplet at 8.2 ppm. Complexation of calcium to H6ntmp was 
readily observed by 31p NMR (Figure 1.21). As more CaC03 was added to the 
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(a) 
Figure 1.19. VSI maps of sample 20 surface (80x objective) showing the initial surface 
(a), and reaction sequence of this surface exposed to H6ntmp solution at 15 min (b), 30 
min (c), and 1 h (d). 
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(a) 
(b) 
Figure 1.20. VSI maps of sample 20 surface (lOx objective) of the initial surface (a) and 
reaction of this surface exposed to citric acid solution at 1 min while removing solvent 
(b), at 1 min. after solvent removal ( c). 
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(a) 
(b) 
Figure 1.21. VSI maps of sample 20 surface (80x objective) of the initial surface (a), and 
reaction sequence of this surface exposed to fructose solution at 1 h (b), and 3 h ( c). 
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H6ntmpID20 solution, the intensity of the triplet peak decreased, signifying the formation 
of the calcium phosphonate complex. 
Complexation of H6ntmp with sample 20 was also examined using the same 
procedure specified above. The 3lp NMR spectra of this sample showed ligand formation 
patterns that are very similar to the ones observed with our reference CaC03 material 
(Figure 1.22). This result is very encouraging and provides conformation that H6ntmp 
ligand indeed binds well to our synthetic sample and could possibly be used as a therapy 
for human CBK samples as well. 
To study the ability of citric acid to chelate with calcium IR studies were 
conducted to adduce that calcium is binding to citric acid. The C-O stretch for carbonyl 
(,...,1710 cm- l ) and C-O stretch (1200 cm- l ) will shift to a lower frequency with the addition 
of calcium material.28 In addition, the OH stretch will begin to disappear due to the 
chelation to the calcium. These changes in the IR signify the formation of the calcium-
oxygen complex. The IR spectra of citric acid and citric acid and sample 20 mixture were 
collected dried from solvent. Figure 1.23, is an overlap of the original IR taken before 
sample 20 was added and after. As predicted there are shifts in the carbonyl and C-O 
stretch due to the addition of our calcium containing sample. It appears that sample is 
forming the Ca complex with the citric acid. This complex will not precipitate and will 
remain in solution till removed as our VSI experiment revealed earlier. Therefore, we 
believe that citric acid makes a promising therapeutic candidate for human CBK samples. 
Conclusions 
In developing an ex-situ model for subsequent studies, we have shown that in 
order to mimic the morphology and composition of human samples, there are three 
components that are required: 1) a calcium source, 2) a silicon source, and 3) a surfactant 
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Figure 1.22. 31 p NMR spectra ofH6ntmp solution (a) and its reactions with 2 mg (b), 6 
mg (c), 10 mg (d), and 14 mg (e) ofCaC03• 
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Figure 1.23. 31 p NMR spectra ofH6ntmp solution (a) and its reactions with 2 mg (b), 4 
mg (c), 8 mg (d), and 16 mg (e) of sample 20. 
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Figure 1.24. IR of citric acid and citric acid complex. 
-like or lipid-like molecule. 
Both the human samples and our model materials suggest that the Si:Ca ratio can 
vary over a range of at least 0.2 - 2.0 without significant alteration in morphology other 
than the size of the spherical structure. The identity of the silicon source in our model 
compounds appears to be flexible to some extent as shown by similarities of samples 
prepared with silica or silicones. Certainly, the potential of silicones as a nidus can be 
related not only to silicone oils used in surgery, but also silicones present in the 
production process and packaging for a wide range of products including ophthalmic 
drops. 
The choice of SDS as a surfactant additive was based upon our prior experiences; 
however, our results suggest that the identity of the surfactant is less important than its 
presence. Thus, we suggest that any lipid-like molecule comprising a charged functional 
group (e.g., sulphate, phosphonic acid, carboxylic acid, etc) and an aliphatic 
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(hydrophobic) tail will be sufficient. Furthermore, the presence of a mixture of organic 
non-polar compounds that are present in the human eye also appears to be flexible, as 
indicated by the ability to generate suitable structures in the presence of hexane. 
We have shown that a silicon source and calcium carbonate mixed with water in 
the presence of a surfactant molecule under physiological pH and temperature produces a 
substance that resembles biological calcium band keratopathy samples, and thus 
providing insight to the conditions necessary for deposit formation. In addition, we have 
developed a way to mimic the morphology and composition of the biological samples 
that allows for mass production of the material furthering the advances of therapeutics 
targeting CBK. This model has enabled us to further our study in search of a lead for new 
more patient friendly therapies for CBK. 
Our studies for medicinal effect of nitrilo-tris(methylene )phosphonic acid, 
N[CH2PO(OH)213 (H6ntmp), revealed that this compound is highly effective at the 
complexation and extraction of calcium material from our synthetic model. Citric acid, 
our other calcium extracting candidate, also showed to be extremely efficient in 
dissolution of our synthetic sample. Despite our initial observation of fructose ability to 
dissolve fume silica, our studies on our synthetic CBK sample did not reveal similar 
results. No dissolution or surface topography change was observed. Further research in 
the applicability of H6ntmp and citric acid as therapeutic agents on human CBK samples 
is of great importance and looks very promising. 
Further investigation into medicinal effect of these two complexing agents on the 
human CBK precipitates is essential. To ascertain the safety and toxicity aspects of these 
agents, and their applicable dosage for human eye, in-vitro cell studies are needed. The 
effect of the slightly acidic solution (pH of 6.5) in the neutral environment of the eye 
must also be determined. The emerging therapeutic drugs may bear some unknown 
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factors along with lack of long term exposure risks but generally their curative benefits 
could overcome their drawbacks. 
Experimental 
Calcium carbonate, fumed silica, sodium dodecyl sulfate (SDS), 
tetradecylphosphonic acid (TDPA), silicic acid, silicon oil, and dodecane were purchased 
from Sigma-Aldrich. Hexane, hydrochloric acid and sodium hydroxide and D20 were 
purchased from Fisher Scientific. Carbon dioxide was purchased through Matheson 
Trigas. Ultra pure (UP) water was obtained from a Millipore Milli-Q UV water filtration 
system. All reagents were ACS grade or better and were used as received. Human eye 
samples were obtained from patients at the Cullen Eye Institute at Baylor College of 
Medicine, Houston, TX. 
SEM images were observed on a FEI Quanta 400 ESEM. The samples were 
attached to a stub using carbon tape and then sputtered with a thin layer of gold to 
prevent charging. Powder X-ray diffraction studies were performed on a Rigaku 
diffractometer. Samples were attached to a glass slide using a 5 - 100° angle range. XPS 
data was acquired on a Phi Quantera system using an aluminum X-ray at a 45° angle. 
Raman data was collected on a Renishaw Raman Microscope with a 785 nm laser power. 
Precipitation reaction of calcium carbonate without hydrocarbon. A 
summary of experimental variations is given in Table 1. An appropriate quantity of 
CaC03 was added to deionize water (100 mL). This solution was then allowed to stir in 
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an oil bath at 36°C for one hour with CO2 bubbling through the solution. After an hour, 
silicon reagent and/or surfactant were added to the calcium solution and stirring resumed 
at 36 °C with C02 bubbling again for a time period ranging from 4 to 24 hours. The 
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reaction was then allowed to rest without stirring but in a heated environment for 24 h. 
The resulting precipitate was collected by vacuum filtration. 
Precipitation reaction of calcium carbonate in the presence of hydrocarbon. 
A solution of CaC03 was prepared by dissolving a determined quantity of CaC03 in 
deionize water (100 mL). The solution was then stirred at 36 DC for an hour while CO2 
bubbled through the solution. Then, the silicon reagent, surfactant, and hydrocarbon were 
added to this solution and stirring resumed at 36 DC with CO2 bubbling again. The 
reaction time and amounts of reagents varied according to Table 2. The reaction was then 
allowed to sit with heat for 24 h and the resulting precipitate was collected by vacuum 
filtration. 
It must be noted that multiple samples of each sets of precipitated were grown in 
order to confIrm the reproducibility of the methods. In each case the elemental analysis 
was within experimental error and the morphologies were identical. 
Vertical scanning interferometry. Solutions of 5% sample 20 was placed and 
fIxed in a commercial epoxy resin and allowed to dry overnight. Resin was then cured at 
125 DC and 176 DC, respectively, and the surface was polished. The fIxed sample was 
mounted with constant orientation and position on the interferometer's stage. Sample was 
then reacted with a flowing solution of fIxed composition for discrete time intervals, 
solution was dried after each time interval and VSI surface topography measurements 
were acquired. The change in surface topography of sample surface was monitored using 
lOx objective which allows mapping of a relatively large area of the sample surface (~0.5 
mm2 fIeld of view) at subnanometer vertical resolution. Surface topography images were 
also taken at 80x objective as well. For VSI measurements, 5% solutions of H6ntmp, 
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citric acid and fructose in DI water were prepared and pH was adjusted to 6.5 with NaOH 
or HCI. 
NMR and IR spectroscopy. Solution 31p NMR spectra were obtained on a 
Bruker Avenue 400 MHz spectrometer at 161.9 MHz. Proton-decoupled spectra were 
collected using a 9.6-J.ls pulse based on 90° pulse width calibrations with 85% phosphoric 
acid and a 3.0 s relaxation delay. The samples were externally referenced to 85% H3P04 
at 0.0 ppm. IR spectra were obtained using a Nicolet FTIR spectrometer. 
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Chapter 2 
Biological Effects of Functionalized Buckminsterfullerene (C60) 
Introduction 
This year marks the silver anniversary of the discovery of the most abundant, 
symmetrical and stable form of fullerene clusters, Buckminsterfullerene (C60). Following 
its discovery in 1985 1 and macroscopic-scale synthesis in 1990, 2 covalent 
functionalization of this nanosphere for various applications in diverse scientific fields 
ranging from material to biomedical sciences has burgeoned. The unique structural, 
physical, and photo-, electro-chemical properties of the C60 core and its derivatives 
renders them particularly interesting for various biomedical and biotechnological 
applications. Some researchers have reported antioxidant and free radical scavenging and 
quenching properties of functionalized C60 derivatives.3 Other investigators have studied 
the theraputic and diognostic imaging cabailities of C60 derivatives.4 
Potent inhibitors of human immunodeficiency virus type I aspartic protease (HI V -
1 P) have been developed and used as drugs, however, the nature of majority of these 
drugs is peptide-like rendering limited oral bioavailability and half-life.5 In search of 
more efficient and non-peptidic inhibitors of HIV -1 P enzyme, the particulat size and 
geometrical shape of C60 fullerene draw researchers attention. Initial molecular modeling 
studies revealed it as an ideal inhibitor of this enzyme, especially if additional 
interactions, besides hydrophobic interactions can be obtained.6 The active site of the 
HIV -1 P is approximately an open-ended cylindrical hydrophobic cavity with a diameter 
of about 1 nm.5 There are hydrophobic and hydrophilic amino acid residues inside the 
cavity of the HIV -1 P enzyme. Derivatization of the fullerene at specific positions with 
groups that may give hydrophobic or electrostatic interactions with these amino acids 
may increase the inhibitory effects of these derivatives considerably. Many fullerene 
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derivatives have since been synthesized and tested against HIV -1 P by several 
experimental groupS.7 The most active fullerene-based inhibitor currently available has 
an inhibitory binding (Ki) of 103 nM. 
Molecular docking simulations, performed by our collaborators, revealed 
particular promise for a group of fullerne-based amine and amino acid derivatives that 
were formerly synthesized and characterized by our group.8 Considering the theoretical 
observed significant inhibitory effects of these fullerene derivatives and the urgent need 
for new anti-HIV drugs, we synthesized these series of C60 derivatives in order to further 
study their inhibitory effects against HIV -1 P experimentally. 
Hydrophobic cleft is a characterizing feature of the active site of many enzymes. 
Therefore, C60 may be envisiond as fitting these clefts and through intermolecular 
interactions provide a significant inhibitory effect. Indeed, C60 derivatives have shown 
inhibit activity against variuos other enzymes.9 As a part of this research, we became 
interested in studing potential inhibitory effects of our fulleme derivatives for a group of 
carbonic anhydrase enzymes. 
Carbonic anhydrases (CAs) form a family of metalloenzymes that catalyze 
conversiaon of carbon dioxide and water to bicarbonate and protons (Eq. 2.1). This 
simple reaction is very crucial in physiological processes connected with respiration and 
transport of C02lbicarbonate between tissues and lungs, pH and C02 homeostasis, 
electrolyte secretion in a variety of tissues/organs, biosynthetic reactions, bone resorption, 
calcification, tumorigenicity, and many other physiologic or pathologic processes. 10 
Therefore, CA enzymes have recently emerged as potential novel therapeutic targets for 
design of inhibitors to treat a range of disorders including glaucoma, obesity, cancer, 
epilepsy, and osteoporosis. 10 The a-CAs, ~-CAs, y-CAs, and 8-CAs are all members of 
the CA enzyme family. At least 16 isozymes of a-CAs have been identified in mammals 
with very differtent subcellular localization and tissue distribution. These mammalian 
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isozymes are divided into four subgroups according to their location or distribution: the 
cytosolic forms, the membrane-bound isoforms, the mitochondrial forms and a secreted 
isozyme. 10 
(2.1) 
The opening of the active site cleft of the a-CAs is about 1.5 nm and contains a 
zmc ion (Figure 2.1) which is coordinated to the imidazole rings of three histidine 
residues, His 94, His 96 and His 119, and a hydroxide ion (not shown). With a diameter 
of about 1 nm, C60 fullerene might be an interesting candiadate to be investigated for its 
interaction with CAs. In fact, proir to this research, fullerene and its derivatives had not 
been studied for their interactions with CAs. Therefore, we investigated, in the course of 
a joint effort, wether our fulleme-based amine and amino acid derivatives may show 
inhibitory activity against all mammalian isoforms. 
In drug development, disease diagnosis and disease treatment, the ability of the 
therapeutic and diagnostic moieties to selectively reach the desired targets with marginal 
or no collateral damage is of the utmost importance. An ideal therapeutic or imaging 
contrast system would also encompass the ability to overcome the biological barriers that 
prevent it from reaching its target. II C60 fullerene materials have been studied for use in 
nanomedicine and show great promise for crossing cell membranes and even producing 
transfection.12 Previuos research conducted by our group has shown the transport of a 
fulleme based amino acid-peptide conjugate into a cancer cell. 13 In this conjugate system, 
the fullerene acted as a passport for intracellular delivery of peptide into the cell where 
the peptide in the absence of the fullerene amino acid could not enter the cell. This 
fulleme based amino acid-peptide conjugate was also capable of inhibiting proliferation 
of nueroblastoma cells at low concentration.13 
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Figure 2.1. Active site of a-CA enzymes (Zn2+ is shown as a pink sphere and histidines 
in green). 10 
Neuroblastoma is the most common extracranial solid tumor in infants and young 
children and accounts for about 15% of pediatric cancer death. Despite advances in 
treatment options, aggressive nueroblastomas remain unmanageable and additionally, 
current therapies present significant acute and chronic drug toxicity. Among the 
biological markers that have been identified in paitents with neuroblastoma, N-myc 
oncogen is the most important one. 14 N-myc is amplified in approximately one quarter of 
nueroblastoma cases and is more common in patients with advanced stage disease. 
Overexpression of this oncogen is associated with rapid tumor progression and a poor 
prognosis for paitents. 14 Identification of effective and selective inhibitors of N-myc 
would be important for the development of therapuetic agents for neuroblastoma. A 
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major clinical limitation of currently designed inhibiros of N-myc is their rapid 
degradations. IS Our fu1lerne based amino acid-peptide conjugate showed no degradation 
when expose to bovine plasma suggesting that fullerne amino acid linkage to peptide 
might be stable under physiological conditions.13 Considering the promising features of 
our reported full erne based amino acid-peptide conjugate, we identified and synthesized a 
series of potential inhibitory fullerene peptides derived from the HI binding domain of 
the N -myc protein that can bind with this domain and restrain its amplification. 
Result and Discussion 
All C60 derivatives for mv and CA inhibition studies were prepared and 
characterized according to previously reported methods (Figure 2.2).8 
(2.1) 
*Cl "'C2 
o 
~OH 
'" NA) H~,Boc 
H 
(2.3) 
(2.6) 
*Cl *C2 
(2.2) 
~ f"YNHBoC 
~~AJ 
(2.5) 
Figure 2.2. Compounds synthesized for HIV -1 P and CAs inhibition studies. 
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HIV inhibition studies. Molecular docking simulation studies conducted by our 
collaborators showed that compounds 2.1 through 2.6 have higher or slightly lower 
affinity for HIV -1 P in compare to previously reported fullerene derivatives. The higher 
affinities are connected with the ability of pendant groups to form H-bonds with the 
catalytic site of the enzyme as well as the van der Waals interactions between the 
fullerene cage and the nonpolar surface of active site amino acid residues. The binding 
scores of these fullerene derivatives were comparable to the reported most potent 
fullerene-based HIV -1 PR inhibitor (I). Subsequent biological tests were performed for 
these compounds. The results of the computational and biological studies are summarized 
in Table 2.1. Compounds 2.1 and 2.2 showed relatively similar binding energies to the 
currently reported most potent fullerene-base HIV-l P inhibitor, diphenyl C60 alcohol, I) 
both computationally and experimentally. 
(I) 
There are two chiral centers *C1 and *C2 at compounds 2.1, and 2.2 and 2.3 
(Figure 2.2); *C2 has an (S) configuration in compound 2.1 and 2.3 and (R) configuration 
in compound 2.2, but *Cl can have both configurations. Thus, both (S) and (R) 
configurations have been taken into consideration in the docking simulations. It was 
noted that compounds that have an (S) configuration at *C1 show slightly better binding 
energies than the corresponding (R) configuration (-1 - 4 kJ/mol) (Table 2.1). The 
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position of the best binding energy poses from molecular docking simulations of 
compound 2.1 with (S) and (R) configurations at *C1 is similar at the binding pocket of 
HIV-1 PR. This compound with an (S) configuration at *C1 forms four H-bonds with 
Arg8 and Asp30'; and compound with an (R) configuration at *C1 forms three H-bonds 
with Arg8, Asp30', and Gly48' (Figures 2.3 and 2.4). In addition, van der Waals 
interactions are observed between the nonpolar unsubstituted fullerene cage of this 
compound with nonpolar moieties of residues such as Leu23, Ala28, Va132, Ile47, Ile50, 
Gly52, Phe53, and Pro81 ofHIV-1 PR. 
Table 2.1. Comparison of experimental and computational binding energies the fullerene 
derivatives at HIV -1 P. 
Binding Energy (kJ/mol) 
Compound Computational Experimental 
I -36.66 -40.13 
2.1 -37.60 (*C1, S) -39.75 
2.1 -36.56 (*C1, R) -39.75 
2.2 -35.81 -39.67 
2.3 -33.23 -36.52 
2.4 -30.82 -29.75 
2.5 -31.3 <-28.72 
2.6 -26.8 <-28.72 
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Figure 2.3. The binding interactions of compound 2.1 with (S) configuration at *C1 with 
the active site residues of HIV -1 P. 19 
F or comparison purposes, docking simulations were performed for compound I as 
well. These simulation showed that compound I forms only two H-bonds with Asp25' 
and Ala28' (Figure 2.5). The van der Waals interactions of its nonpolar surface are 
observed with nonpolar segments of HIV-1 PR residues (e.g., Leu23, Ala28, Va132, 
Ile47, Ile54, Pro81, Va182, and Ile84). In addition, compound I shows van der Waals 
interactions between its phenyl substituent with VaI82'. The presence of multiple 
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functional group on of our fullerene derivatives offers the opportunity of further 
derivatization of these fullerenes which may improve their inhibitory effects considerably 
through increased hydrophobic or electrostatic interactions with the hydrophobic and 
hydrophilic amino acid residues of the enzyme' s active site. These results and features of 
our fullerene derivatives show that new leads can be discovered possessing higher 
bioactivity against HIV -1 P. 
Figure 2.4. The binding interactions of compound 2.1 with (R) configuration at *C 1 with 
the active site residues ofHIV-1 p.19 
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Figure 2.5. The binding interactions of compound I with the active site residues of HIV-
1 p.19 
CAs inhibition studies. All compounds listed on Figure 2.2, except compound 
2.2, and compound I were investigated for CAs inhibition by our collaborators. Inhibition 
data for these compounds against all 13 catalytically active mammalian (h = human, m = 
murine) CA isoforms, CA I-IV, VA, VB, VI, VII, IX, XII-XV, are presented in Table 
2.2. Several CA isozymes were potently inhibited by all our fullerene derivatives, with 
inhibition constants in the submicromolar range (Kjs of 0.61-0.93 ~M), among which are 
the tumorassociated hCA XII, and the transmembrane ones hCA XIV and mCA XV. The 
structure-activity relationship (SAR) is quite straightforward, with all derivatized 
fullerenes showing good activity. For example, the best inhibitor against hCA XII was 
the p-phenylenediamine derivative 2.4 (Ki of 0.61 ~M). The protection of the amino 
group with the Boc moiety, as in 2.5, or the bis-phenylenediamine 2.6 led to a slightly 
diminished activity compared to 2.4. The same is true for the bulkier compounds 2.1, and 
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2.3 as well as for the compound I, but these derivatives also showed considerable hCA 
XII inhibitory activity. Compound I was the inhibitor for HCA XIV. 
Table 2.2. Inhibition of mammalian carbonic anhydrase isozymes with fullerene 
derivatives. 
Isozyme 
2.1 2.3 
hCAI 8.82 9.31 
hCAII 9.05 9.38 
hCA III 9.58 9.42 
hCAIV 7.04 12.3 
hCAVA 111 94.4 
hCAVB 87.6 28.6 
hCA VI 5.98 6.07 
hCA VII 10.6 10.94 
hCAIX 13.4 14.32 
hCAXII 0.67 0.76 
hCA XIII 7.64 8.73 
hCAXIV 0.9 0.88 
mCAXV 0.83 0.81 
h = human, m = murine isoforms. 
Ki (~M) 
2.4 
9.63 
9.38 
8.77 
6.44 
51.8 
40.6 
0.89 
9.82 
12.9 
0.61 
8.75 
0.93 
0.9 
2.5 
9.54 
8.75 
8.91 
11.5 
50.3 
27.7 
5.91 
10.58 
11.07 
0.66 
8.78 
0.89 
0.89 
2.6 I 
7.95 7.57 
6.73 16.6 
8.23 8.9 
94.5 3.66 
85.9 49.7 
64.5 38.3 
1.04 0.87 
12.59 10.31 
12.87 7.93 
0.73 0.73 
8.71 7.57 
0.84 0.77 
0.82 0.82 
The only secreted isoform, hCA VI, showed a more intricate inhibition profile 
with the fullerenes. Indeed, the less bulky compound 2.4 was submicromolar inhibitors 
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(Kjs of 0.87 - 0.89 JlM), the bisamine 2.6 had a Kj of 1.04 JlM, whereas the remaining 
compounds were less inhibitory, with Kjs in the range of 5.91-8.50 JlM. In this case it 
may be stated that the compounds with more compact moieties (such as 2.4, and 2.6) 
were the best inhibitors. 
A large number of CA isozymes such as hCA I, II, III, VII, and XIII (cytosolic 
CAs) and the tumor-associated transmembrane and tumor-associated CA IX were 
inhibited by all our fu1lerenes in the low micromolar range, with inhibition constants 
typically in the range of 7 - 15 JlM. The ubiquitous and catalytically very efficient hCA 
II was best inhibited by the bisamine 2.6. hCA VII was slightly less susceptible to this 
fullerene class of inhibitors compared to hCA I. The tumor-associated hCA IX showed 
inhibition constants with all fullerenes in the range of7.93 - 14.32 JlM. The best hCA IX 
inhibitor was compound I, whereas the least effective one was the Boc-substituted Phe 
derivative 2.3. Thus, even for a small series of derivatives relatively minor structural 
changes influence the CA inhibitory activity significantly, this is promising in designing 
a totally new class of inhibitors. 
The extracellular isoform hCA IV, similar to hCA VI, shows a very typical and 
unique inhibition profile with these compounds (Kjs in the range of 3.66 - 94.5JlM). Thus, 
the bisamine 2.6 is a very ineffective hCA IV inhibitor, whereas compound 2.4 is 
effective one. Thus, the difference of activity between the two structurally related 
compounds 2.4 and 2.6 is important, with the monoamine 2.4 being 14.7 a better hCA IV 
inhibitor compared to the bis-derivative 2.6. The remaining compounds 4-6 showed an 
intermediate activity between these extremes, with Kjs in the range of7.04 - 12.30 JlM. 
The two mitochondrial isoforms hCA V A and hCA VB were the least inhibited 
ones by the fullerenes 1 - 7. Indeed, these compounds showed inhibition constants in the 
range of27.7 -111 JlM against these two enzymes. 
68 
All these data clearly show that each of the 13 catalytically active CA isozymes 
has a particular inhibition profile with our fullerenes. Furthermore, the SAR for this small 
series of derivatives is rather complex, with a range of inhibition constants from the 
submicromolar to submillimolar, which makes this class of derivatives of particular 
interest in developing nanoscale CAIs. 
Molecular docking studies were performed by our collaborator in order to 
investigate the interactions between fullerenes and amino acid residues within the CA 
active site. Two CA isozymes (CA II and CA IX) were used in these docking studies. For 
both CA isoforms, the fullerene binds in similar active site region, as shown in Figure 2.6. 
Docking binding scores for these fullerenes within the CA II and IX active sites varied 
between -6.02 kcal/mol and -9.36 kcallmol (i.e., from micromolar to submicromolar 
binding affinity, Table 2.2), which is within the same range as those obtained 
experimentally Table 2.3. 
Figure 2.6. Binding of fullerene 2.1 to hCA II (shown as ribbon representation of the 
amide backbone). The catalytic Zn(II) ion is the yellow sphere at the center of the 
molecule.2o 
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Table 2.3. Computational binding energies of fullerene derivatives to CA II and CA IX. 
Compound CA II (kcal/mole) CA IX (kcal/mol) 
I -6.66 -7.90 
2.1 -9.14 -6.63 
2.3 -7.95 -8.47 
2.4 -6.76 -6.02 
2.5 -7.31 -6.03 
2.6 -6.95 -6.49 
The fullerene cage was observed to be located at the entrance of the CA active 
site when interacting with both CA isozymes, CA IIand IX, thus occluding the entrance 
of substrates or other molecules within the cavity. The amino acid residues involved in 
these interactions were His64, His94, His96, Va1121 , and Thr200 (Figure 2.7). The 
docking studies showed that hCA II was best inhibited by compound 2.1, whereas the 
worst inhibitor was compound I, which was found also experimentally to be the worst 
inhibitor of this isozyme. Thus, there is a good agreement between the experimental and 
computational studies regarding the interaction of hCA II/IX with fullerenes 2.1, and 2.3 
- 2.6. 
Compound 2.3 showed good inhibition against isozyme hCA IX. Its binding to 
this isoform is represented in Figure 2.8, as obtained by the docking procedure. Although 
compound 6 has similar binding scores with hCA II and IX, the location of the fullerene 
cage showed different locations within these isozyme active sites. In hCA II, the fullerene 
cage was located more outwards within the active site compared to its binding to the hCA 
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IX active site (Figure 2.9). Since the binding scores were similar for these two isozymes, 
this is a confirmation that the pendant groups present in the fullerene molecule have an 
important role in the inhibition of the diverse CA isozymes. Thus, the main finding of 
these molecular modeling studies is that the fullerene cage binds at the entrance of the 
CA active site and occludes it, inhibiting the enzymes in a manner similar to that of the 
coumarins, the recently discovered CAIs. 16 A second significant finding is that the 
pendant groups present in the fullerene derivative strongly influence the interaction of the 
inhibitor with amino acid residues found at the entrance of the active site cavity. As these 
residues are generally different between the various CA isozymes, this can lead to 
isoform-selective CAIs. This has been observed experimentally in the small library of 
derivatives investigated here and confirmed by means of the docking studies. 
Figure 2.7. Binding of fullerene 2.5 to hCA H as obtained by the induced fit docking 
method. Yellow and green dashed bonds show H-bonds and close-van der Waals contacts, 
respectively. The catalytic Zn(H) ion is shown as orange spheres.2o 
Neuroblastoma cell growth studies. Myc-family proteins are transcription 
factors with an apparent role in transcription or DNA replication. 17 Elevation in the levels 
71 
of Myc proteins is associated with carcinogenesis. The Myc-family proteins contain a C-
terminal region including a basic helix-Ioop-helix/leucine zipper (bHLH-LZ) motif 
(Figure 2.10). A recent study has identified that a 14-amino acid modified peptide 
derived from the HI region of c-Myc can interfere in vitro with specific DNA binding 
and inhibits cancer cell growth. 18 Amino acid substitutions (mutations) at nonconserved 
residues were made in the helix-l peptide of c-Myc with a strategy of conferring greater 
helical content to these peptides and increasing their heterodimeric function. Amino acids 
leucine and serine were substituted by alanine in order to provide helix stabilization in 
these peptides and which in tum provided a surprising inhibitory effect. 
Figure 2.S. Binding of compound 2.3 to hCA IX. Yellow and green dashed bonds show 
H-bonds and close-van der Waals contacts, respectively. The catalytic Zn(II) ion is 
shown as the yellow sphere.2o 
Therefore, we chose the peptides for neuroblastoma inhibition studies from the 
HI region of the n-Myc protein which is amplified in neuroblastoma cells and modified 
them accordingly. For each parent peptide sequence the fullerene substituted 
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phenylalanine (noted as Baa hereafter) peptide derivatives were also prepared and 
compared to their parent non-fullerene containing sequence. We investigated the effect of 
fullerene on the cellular uptake of these peptides and also whether these peptides show 
any inhibitory activity for neuroblastoma cell proliferation. To visualize the fullerene 
peptide inside the cells, fluorescein isothiocyanate (FITC) was introduced as a label. The 
fullerene derivatives were prepared by SPPS on preloaded crude peptide on wang resin. 
In the case of the parent sequences, a phenylalanine was coupled to the end to mimic the 
phenylalanine structure of the Baa residue. 
Figure 2.9. Superimposition of hCA II (shown in yellow colored ribbons) and hCA IX 
(shown in green colored ribbons) docking complexes of fullerene 2.3. Dark colored 
fullerene shows the binding pose at hCA II and light colored fullerene shows the binding 
pose at hCA IX. The Zn(II) ion is shown by yellow (for hCA II) and green (for hCA IX) 
sphere, respectively.2o 
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Basic Region HelIx 1 Hel,x 2 Zipper 
Figure 2.10. The basic helix-Ioop-helixlleucine zipper ofMyc family proteins. ls 
All appropriate peptides were prepared according to previously reported methods 
and characterized by MALDI-TOF MS spectroscopy. MALDI-TOF mass spectra show 
the parent ion (~+H) and ~+H-FITC for each peptide. The specific sequences 
investigated along with the cell lines employed are in Table 2.4. 
The cellular uptake study was conducted by our collaborators using JF cell lines. 
The fluorescence images of the parent peptides 2.9 revealed no significant uptake in the 
cells. However, the Baa analogue of that peptide, 2.12, showed some localized intense 
fluorescence in the cytoplasm of the cells (Figure 2.11). It appears that the addition of the 
Baa residue to the sequence facilitated the intracellular localization of the peptide 2.12. 
The effect of the Baa-peptide sequences on the cell viability of SH-SY5Y 
neuroblstoma cells were investigated to determine if the sequence has an effect rather 
than the presence of the C60. Exposure of SH-SY5Y cells to the Baa-peptides for 48 hrs 
showed no significant inhibition of cell growth by Baa-peptides 2.10 and 2.11, but Baa-
peptide 2.12 showed significant inhibition towards this cell line (Figure 2.12), 
specifically at 40 /lM. Clearly the sequence could have a significant effect on the cell 
viability, however, it must be noted that this result could be due to differences in the 
cellular uptake of these sequences or formation of aggregates in the cell. 
A similar comparison has been made with the same cell line using the parent 
peptides 2.7 - 2.9 (Figure 2.13). The parent peptides 2.7 and 2.8 show no significant 
inhibition just like their Baa analogues while peptide 2.9 shows slight effect at the higher 
concentration (40 /lM) (Figure 2.13). This result could be an indication that the inhibition 
effect is indeed related to the peptide sequence not the presence of fullerene. 
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Table 2.4. Peptide sequences and cell lines studied. 
Peptide Sequence Cell linea 
2.7 F -K(FITC)-NDLRSSFLTLRDHV SH-SY5Y, IMR32, 
MCF-7, LAN-l 
2.8 F-K(FITC)-NDLRSSF A TLRDHV SH-SY5Y, IMR32, 
MCF-7, LAN-l 
2.9 F-K(FITC)-NDLRSAF ATLRDHV JF, SH-SY5Y5, 
IMR32, MCF-7, LAN-l 
2.10 
2.11 
2.12 
Baa-K(FITC)-NDLRSSFLTLRDHV SH-SY5Y,IMR32, 
MCF-7, LAN-l 
Baa-K(FITC)-NDLRSSFATLRDHV SH-SY5Y,IMR32, 
MCF-7, LAN-l 
Baa-K(FITC)-NDLRSAFATLRDHV JF, SH-SY5Y, IMR32, 
MCF-7, LAN-l 
a SH-SY5Y, JF, IMR32 = neuroblastoma cancer cells, MCF-7 = breast cancer cell line. 
A much unexpected result was observed when the inhibitory effects of the Baa 
peptides and their parent peptides were tested against the proliferation of neuroblastoma 
cell lines IMR-32 and LAN-l and breast cancer cell line MCF-7. While none of the 
parent peptide show significant inhibitory effects, their Baa peptide conjugate activated 
the proliferation of these cells (Figure 2.14-2.16). Although we have not yet explored the 
underlying cause of this activation process, this effect if observed with other cell lines 
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might constitute a possible therapeutic approach for degenerative illnesses where cell 
growth is haltered. 
Figure 2.11. Fluorescence images of JF cell incubated with (a) F-K(FITC)-
NDLRSAFATLRDHV and (b) Baa-K(FITC)-NDLRSAFATLRDHV. 
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Figure 2.12. Inhibition of fullerene peptides against the proliferation of neuroblastoma 
cell line (SH-SY5Y), (2.10, e), (2.11 , e), and (2.12, ). 
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Figure 2.13. Inhibition of fullerene peptides against the proliferation of neuroblastoma 
cell line (SH-SY5Y), (2.9, e), (2.10, e), and (2.11, ). 
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Figure 2.14. IMR-32 neuroblastoma cell line proliferation in DMSO, and Baa-peptides 
2.10 and 2.12. 
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Figure 2.15. LAN-l neuroblastoma cell line proliferation in DMSO, and Baa-peptides 
2.10 and 2.12. 
78 
3_5 
-+- DMSO 
3 
--II- 2.10 
2_5 -.A 2.12 
Optical 2 
DellSlty L5 
1 
0_5 
0 
M OpM 400 
Concentration of fuDerne peptide 
Figure 2.16. LAN-l neuroblastoma cell line proliferation in DMSO, and Baa-peptides 
2.10 and 2.12. 
Conclusions 
In search of discovery and expantion of possible novel applications of our current 
library of fullerne materials, we have learned that a series of these functionalized 
fullerenes have anti-HIV acitivities similar to the most acitve fullerene based inhibitors 
currently available. The presence of multiple functional groups offers an opportunity for 
further functionalization of these series in order toamplify their inhibitory effect. 
We discovered that these derivatives can also bind to thirteen different 
mammalian isoforms of CAs with submicromolar-Iow micromolar affinity. By means of 
computational methods the inhibition mechanism of the fullerene derivatives was 
identified as being due to occlusion of the active site by means of the fullerene cage 
(possessing dimension of the same order of magnitude with the opening of the enzyme 
cavity). The pendant moieties to the fullerene cage will then interact with amino acid 
residues from the active site. Fullerenes thus represent a totally new class of nanoscale 
79 
CA inhibitors which may show applications for targeting physiologically relevant 
isoforms such as the dominant CA II and the tumor-associated CA IX, which represent , 
established drug targets. 
The reverse outcome of our fullerene peptides for inhibition of neuroblastoma cell 
proliferation was unanticipated. A more comprehensive and through investigation is 
required to understand and confirm the activating effects of these fullerene peptides. 
Experimental 
Peptide sequences were purchased on resin from Biosynthesis Laboratory. 
Fullerene was purchased from MER and used as received. Amino acids and FITC were 
obtained from Novabiochem and used as received. MALDI-TOF mass analysis was 
performed on Autoflex MALDI-TOF. All solvents were dried before use. All C60-
peptides for neuroblastoma inhibition studies were prepared and characterized by 
MALDI -TOF mass spectroscopy according to previously reported methods. 13 Purification 
of all peptides was carried out on an Phenomenex Luna C5 column using isocratic 
gradient of A: 0.1% TFA in water, B: 0.1% TFA in isopropanol, 70% B, at 5.0 mLimin 
flow rate. 
F-K(FITC)-NDLRSSFLTLRDHV (2.7). MALDI-MS: mlz calculated 2355 [M+], 
1965 [~-FITC], found 2355 and 1965. 
F-K(FITC)-NDLRSSFATLRDHV (2.8). MALDI-MS: mlz calculated 2314 
[M+], 1924 [~-FITC], found 2314 and 1924. 
F-K(FITC)-NDLRSAFATLRDHV (2.9). MALDI-MS: mlz calculated 2298 
[~], 1908 [~-FITC], found 2298 and 1908. 
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Baa-K(FITC)-NDLRSAFATLRDHV (2.10). MALDI-MS: m/z calculated 3127 
[~], 2737 [~-FITC], found 3127, 2737. 
Baa-K(FITC)-NDLRSSFATLRDHV (2.11). MALDI-MS: m/z calculated 3085 
[~], 2696 [~-FITC], found 3085, 2696. 
Baa-K(FITC)-NDLRSSFLTLRDHV (2.12). MALDI-MS: m/z calculated 3069 
[~], 2680 [~-FITC], found 3069, 2680. 
Computational details and inhibition assays for HIV and CAs Studies. 
Computational methods and inhibition assay studies for HIV and CA inhibitions were 
performed by our collaborators and their detail is reported.19,20 
Preparation of fullerene peptide stock solution. Lyophilized fullerene peptides 
and parent peptides were weighed and dissolved in PBS buffer (PH = 7) to make a stock 
solution of required concentration inside a clean hood for neuroblastoma inhibition 
studies. 
Cellular proliferation studies. Inhibition studies for neuroblastoma cell 
proliferation were conducted at by our collaborator at BCM. Cancer cells at 5 x 103 
cells/well were plated in triplicate in standard flat bottomed 96-well tissue culture plates 
in the presence of fullerene peptides in PBS buffer with a final volume of 100 /lL. Cells 
were grown for 48 h at 37°C in a CO2 incubator. Relative cell growth was determined by 
Cell Counting Kit-8 (CCK-8) cell proliferation assay as described by the manufacturer 
using an automated ELISA plate reader. 
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